Abstract
Type 2 diabetes is one of the risk factors for macrovascular disease. Treatment of hypercholesterolemia is important in patients with type 2 diabetes to prevent macrovascular disease. The 3-hydroxy-3-methyl glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are key drugs to lower the cholesterol level not only in nondiabetic patients but also in patients with type 2 diabetes. However, some statins might worsen glycemic control (1) whereas some of them might be neutral (2) or improve glycemic control (3), and their effects on glucose metabolism are controversial. Pitavastatin, an HMG-CoA reductase inhibitor, has been available in Japan since 2003 (4) and the Republic of Korea since 2005, and its effect on glucose metabolism in diabetic patients …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
